VANCOUVER, Sept. 20 /CNW/ - AnorMED Inc. (“AnorMED” or the “Company”) (NASDAQ:ANOR; TSX:AOM) announced yesterday at its Annual General Meeting of Shareholders that the Company remains on track to meet its clinical and commercialization milestones, and commented on the process of realizing maximum value for shareholders through strategic alternatives.
